Document is current

Article History

Accepted: 17 April 2024

First Online: 10 May 2024

Declarations

:

: This study was sponsored by Apellis Pharmaceuticals, Inc., and Swedish Orphan Biovitrum AB. The sponsors also contributed to data interpretation and manuscript development. Writing assistance was funded by Apellis Pharmaceuticals, Inc., and Swedish Orphan Biovitrum AB.

: Brian P. Mulherin has no disclosures to declare. Michael Yeh is an employee of Apellis and holds stock options. Mohammed Al-Adhami was an employee of Apellis at the time of the study. David Dingli serves on advisory boards with compensation from Alexion (AstraZeneca), Apellis, Janssen, Novartis, and Sanofi; and receives research support from K-36 Therapeutics.

: Original study protocols were designed and monitored in accordance with the ethical principles of Good Clinical Practice and the Declaration of Helsinki, and approved by an Institutional Review Board or independent Ethics Committee at each center.

: Patients provided written informed consent before the initiation of study-related procedures.

: Participants consented to publication provided their confidentiality would be maintained, which it is in the data reported in this manuscript.

: The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

: Not applicable.

: All authors contributed to the conception and design of this analysis, the interpretation of data, and the critical revision of the manuscript; agree to be accountable for ensuring the integrity and accuracy of the work; and approved the final version of the manuscript.